Recently published research from the University of Oklahoma and the University of Tulsa shows that a new therapy for children ...

ACRO’s RBQM Working Group has announced the publication of its latest RBM/RBQM paper, Risk-Based Quality Management: A Case for Centralized Mon ...

More than 100 000 women older than 70 years are diagnosed with hormone receptor-positive, early-stage breast cancer each year in the USA.1 A large proportion are at low risk of disease recurrence, ...

On November 8, the Department of Labor (DOL) issued an opinion letter addressing an interesting question under the Family and ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Microbot Medical said Liberty eliminates the need for large and expensive capital equipment and streamlines customers' access ...

New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer ...

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis ...

The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from ...